We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
How to use a randomised controlled trial to evaluate your digital health product.
How to use an N-of-1 study to evaluate your digital health product.
How to use a crossover randomised controlled trial to evaluate your digital health product.
How to use a quasi-experimental study to evaluate your digital health product.
How to use an interrupted time series to evaluate your digital health product.
How to use a micro-randomised trial to evaluate your digital health product.
How to use a factorial randomised controlled trial to evaluate your digital health product.
How to use a multiphase optimisation strategy (MOST) to evaluate your digital health product.
How to use a case-control study to evaluate your digital health product.
How to apply for a clinical trial including eligibility, phases, model IMPDs, costs and how to make changes to your application.
How to use a combination of quantitative and qualitative data to evaluate your digital health product.
Following MHRA approval of a clinical trial, a study on Nuwiq, a recombinant FVIII therapy for the treatment of haemophilia A, can proceed.
How investigators and sponsors should manage clinical trials during COVID-19
Actions that trial sponsors should consider to build resilience into clinical trial design
Past and current clinical trials into therapeutic and antiviral treatments for COVID-19, how to take part, and which treatments have proven to be effective.
Change your protocol, update your authorisation, report safety issues, submit safety updates and complete your end-of-trial study report.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).